Preclinical Development of KYV-201, an Investigational Allogeneic Anti-CD19 CAR T Cell for the Treatment of Autoimmune Disease

Kyverna Therapeutics Inc. published this content on June 11, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 24, 2025 at 22:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]